Zobrazeno 1 - 10
of 112
pro vyhledávání: ''
Publikováno v:
Drug Design, Development and Therapy
Tingting Sun, 1,* Qingquan Wei, 1,* Peng Gao, 1,* Yongjie Zhang, 2 Qing Peng 1 1Department of Ophthalmology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, 200072, People’s Republic of China; 2Department of Human Anatomy, Nanjing
Autor:
Burcu Temizoz, Ken Ishii
Publikováno v:
Expert Review of Vaccines. 20:527-544
Introduction: Innate immunity is armed with interferons (IFNs) that link innate immunity to adaptive immunity to generate long-term and protective immune responses against invading pathogens and tumors. However, regulation of IFN production is crucia
Publikováno v:
Drug Design, Development and Therapy
Xueli Lv,1,* Xiaoxiao Li,1,* Kedi Guo,1,* Tong Li,1 Yuping Yang,1 Wensi Lu,1 Shuting Wang,1 Su Liu1,2 1Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, People’s Republic of China; 2Department of Anesthe
Publikováno v:
Drug Design, Development and Therapy
Man Feng,1 Qinli Feng,2 Yujie Chen,3 Ge Liu,2 Zhuanglei Gao,4 Juan Xiao,5 Chang Feng2 1Department of Pathology, Affiliated Hospital of Shandong Academy of Medical Sciences, Shandong First Medical University, Jinan, 250000, People’s Republic of Chin
Autor:
Fortunato Lombardo, Giuseppe Crisafulli, Tommaso Aversa, Giovanni Battista Pajno, Stefano Passanisi, Lucia Caminiti, Giuseppina Zirilli
Publikováno v:
Expert Opinion on Biological Therapy. 21:1227-1235
Introduction: In recent years, the advent of immunotherapy has remarkably improved the management of IgE-mediated food allergy. However, some barriers still exist. Therefore, the effort of researchers aims to investigate new perspectives in the field
Autor:
Hulya Kasıkara, Levent Ozturk, Mustafa Kavutcu, Mustafa Arslan, Nigar Afandiyeva, Ayşegül Küçük, Nuran Sungu
Publikováno v:
Drug Design, Development and Therapy
Hulya Kasıkara,1 Nuran Sungu,2 Mustafa Arslan,3 Aysegul Kucuk,4 Levent Ozturk,5 Nigar Afandiyeva,6 Mustafa Kavutcu6 1Department of Anaesthesiology and Reanimation, Ankara City Hospital, Ankara, Turkey; 2Medical Faculty, Department of Pathology, Y
Publikováno v:
Expert opinion on biological therapy
Introduction: Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has emerged as an attractive
Publikováno v:
Drug Design, Development and Therapy
Dizhou Zhao, Jieyu Fang, Wei Xiong, Jun Lin, Wanmei Chen, Chujun Wu Department of Anesthesia, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People’s Republic of ChinaCorrespondence: Jieyu FangDepartment of Anesthesia, The Firs
Publikováno v:
Expert Opinion on Biological Therapy. 21:303-309
Introduction: One of the latest breakthroughs in the treatment of advanced Non Small Cell Lung Cancer (NSCLC) is represented by PD-1/PD-L1-targeting Immune Checkpoint Inhibitors (ICIs). However, on...
Publikováno v:
Drug Design, Development and Therapy. 14:5375-5392
Platinum (Pt)-based anticancer drugs such as cisplatin have been used to treat various cancers. However, they have some limitations including poor selectivity and toxicity towards normal cells and increasing chemoresistance. Therefore, there is a nee